Metabogen AB news

BioGaia today announced that its´ subsidiary MetaboGen has reached an important development goal. The first version of its next generation probiotic product is now ready for a safety study.

MetaboGen focuses its research on the microbiome and on finding breakthrough opportunities that can be developed into novel therapeutics and the next generation of probiotics. A number of development programs are now being pursued by the company.

Today, MetaboGen and BioGaia have agreed to initiate a new development program addressing restoration of the microbiome after antibiotic treatment. The program will combine expertise and experience from both companies and is part of the long-term relationship between MetaboGen and BioGaia.

For background, read more here:

The microbiome has gained considerable interest as modulators of health and disease over the past 15 years. The human gut microbiome consists of 500-100

On January 24-26, MetaboGen will attend the 1st Microbiome Drug Development Summit Europe, taking place in Paris. Meet us there!

Read more: http://microbiome-europe.com

MetaboGen expands its operations and opens a new lab facility for product development and anaerobic strain production. The facility is located in Gothenburg, Sweden, and will be in operation from February 1st.